CLAIMS AMENDMENTS:

1. (original) A β-lactamase resistant cephalosporin ester compound, characterized in that the structures of the compound are composed by connecting methyl ester residue of sulbactam halomethyl ester with carboxyl residue of semi-synthetic cephalosporin or salts of thereof.

2. (original) The compound according to claim 1, characterized in that salt of semi-synthetic cephalosporin is inorganic salt or organic alkali salt.

3. (original) The compound according to claim 2, characterized in that the inorganic salt is sodium salt, potassium salt, magnesium salt or calcium salt and the organic alkali salt is triethylamine salt, tributylamine salt, 1.8-diazacyclo[5,4,0]undecane-7-ene salt, dicyclohexyl amine salt or tetrabutylammonium salt.

4. (currently amended) The compound according to ~~any one of claims~~ claim 1 ~~to 3~~, characterized in that the semi-synthetic cephalosporin is cefetamet, cefuroxime, cefradine, cefalexin, cefaclor or cefadroxil.

5. (original) The compound according to claim 1, characterized in that the sulbactam halomethyl ester is sulbactam bromomethyl ester or sulbactam iodomethyl ester.

6. (original) A pharmaceutical salt of the compound according to claim 1.

7. (original) The pharmaceutical salt of the compound according to claim 6, characterized in that the pharmaceutical salt is inorganic salt or organic acid salt.

8. (original) The pharmaceutical salt of the compound according to claim 7, characterized in that the inorganic salt or organic acid salt is hydrochloride, sulphate, *p*-toluenesulfonate, tartrate, maleate and lactate.

9. (currently amended) The compound according to claim 1 ~~or the pharmaceutical salt thereof according to claim 6~~, characterized in that the compound is represented by the following formula (I):



(I)

wherein,

when R is  , R_1 is $-CH_3$ (YR-1)

when R is  , R_1 is $-OCNH_2$ (YR-2)

when R is  , R_1 is $-CH_3$ (YR-3)

when R is  , R_1 is $-CH_3$ (YR-4)

when R is  , R_1 is $-CH_3$ (YR-5)

or, when R is  , R_1 is $-Cl$ (YR-6)

10. (original) A intermediate compound represented by the following formula (IV):



(IV)

wherein, R_1=CH_3 or Cl; R_2=  or  .

11. (currently amended) Use of the compound according to claim 1 ~~or the pharmaceutical salt thereof according to claim 6~~ for preparation of antibiotics.

12. (new) The compound according to claim 2, characterized in that the semi-synthetic cephalosporin is cefetamet, cefuroxime, cefradine, cefalexin, cefaclor or

cefadroxil.

13. (new) The compound according to claim 3, characterized in that the semi-synthetic cephalosporin is cefetamet, cefuroxime, cefradine, cefalexin, cefaclor or cefadroxil.

14. (new) The pharmaceutical salt according to claim 6, characterized in that the compound is represented by the following formula (I):



(I)

wherein,

when R is  , R_1 is $-CH_3$ (YR-1)

when R is  , R_1 is $-OCNH_2$ (YR-2)

when R is  , R_1 is $-CH_3$ (YR-3)

when R is  , R_1 is $-CH_3$ (YR-4)

when R is  , R_1 is —CH_3 (YR-5)

or, when R is  , R_1 is —Cl (YR-6)

15. (new) Use of the pharmaceutical salt according to claim 6 for preparation of antibiotics.